Rosenblum Silverman Sutton S F Inc Alnylam Pharmaceuticals, Inc. Call Options Transaction History
Rosenblum Silverman Sutton S F Inc
- $364 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
638Shares Held
108MCall Options Held
2.33MPut Options Held
2.15M-
Capital World Investors Los Angeles, CA15MShares$4.1 Billion0.61% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.5MShares$3.43 Billion0.06% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.62 Billion0.05% of portfolio
-
Wellington Management Group LLP Boston, MA6.21MShares$1.7 Billion0.28% of portfolio
-
Baillie Gifford & CO6.03MShares$1.65 Billion1.16% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $33.7B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...